Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This trade represents a 5.17 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $17.60 on Friday. The stock has a market cap of $2.32 billion, a P/E ratio of -11.50 and a beta of 1.47. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $16.16 and its two-hundred day moving average price is $12.57. Centessa Pharmaceuticals plc has a twelve month low of $5.58 and a twelve month high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after buying an additional 418,615 shares in the last quarter. Artal Group S.A. raised its stake in shares of Centessa Pharmaceuticals by 39.5% during the first quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after acquiring an additional 400,000 shares in the last quarter. Farallon Capital Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth approximately $4,192,000. Lynx1 Capital Management LP purchased a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at $197,000. Finally, HighMark Wealth Management LLC bought a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at $840,000. Institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CNTA. BMO Capital Markets lifted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Jefferies Financial Group raised their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, Guggenheim upped their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.